INVITED REVIEW
HIF-1: mediator of physiological and pathophysiological responses to hypoxia

Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914

	ABSTRACT

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

All organisms can sense O₂ concentration and respond to hypoxia with adaptive changes in gene expression. The large body size of mammals necessitates the development of multiple complex physiological systems to ensure adequate O₂ delivery to all cells under normal conditions. The transcriptional regulator hypoxia-inducible factor 1 (HIF-1) is an essential mediator of O₂ homeostasis. HIF-1 is required for the establishment of key physiological systems during development and their subsequent utilization in fetal and postnatal life. HIF-1 also appears to play a key role in the pathophysiology of cancer, cardiovascular disease, and chronic lung disease, which represent the major causes of mortality among industrialized societies. Genetic or pharmacological modulation of HIF-1 activity in vivo may represent a novel therapeutic approach to these disorders.

angiogenesis; glycolysis; ischemia; pulmonary hypertension; vascular endothelial growth factor; hypoxia-inducible factor 1

	PHYSIOLOGICAL RESPONSES TO HYPOXIA: FUNDAMENTAL CONCEPTS

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

The ability to maintain O₂ homeostasis is essential to the survival of all invertebrate and vertebrate species. Physiological systems have evolved to ensure the optimal oxygenation of all cells in each organism. In simple invertebrates with few cell layers, direct diffusion of O₂ is sufficient for oxygenation. In Drosophila melanogaster, a series of branching tracheal tubes in the adult fly conduct air throughout the body, thus allowing O₂ to diffuse into individual cells. In humans and other vertebrates, the dramatic increase in body size is associated with the development of a complex physiological infrastructure for O₂ delivery that includes an intake and pumping station (lungs and diaphragm), transport vehicles (erythrocytes), vehicle propulsion device (heart), and highway system (vasculature). The precise establishment and regulation of these systems provide a major basis for O₂ homeostasis.

O₂ sensing was originally attributed solely to specialized chemoreceptor cells such as the carotid and neuroepithelial bodies that regulate cardiovascular and ventilatory rates, respectively (reviewed in Ref. 42). It is now appreciated that all nucleated cells in the human body sense O₂ concentration and respond to reduced O₂ availability (hypoxia) that is either acute or chronic in duration. As in other physiological systems, adaptive responses to acute changes in O₂ concentration (lasting from seconds or less to minutes) principally occur as a result of alterations (e.g., involving phosphorylation or redox state) of preexisting proteins, whereas chronic changes in O₂ concentration (lasting from minutes to hours or more) principally occur as a result of alterations in gene expression. The physiological mechanisms by which cells sense acute or chronic changes in O₂ concentration are only beginning to be understood at the molecular level (reviewed in Ref. 56), and several other mini-reviews in this series on Hypoxia Influences on Gene Expression will tackle various aspects of this important problem.

Not only is O₂ homeostasis essential for survival, but also hypoxia plays an important role in the pathogenesis of major causes of mortality, including cancer, cerebral and myocardial ischemia, and chronic heart and lung diseases. Investigating the molecular mechanisms of O₂ homeostasis therefore represents not only an effort to delineate fundamental aspects of human physiology but also a means of gaining new insights about, and potentially new therapeutic approaches to, the most important public health problems of the present day. This review will specifically focus on responses to chronic hypoxia that involve changes in gene expression that are mediated by the transcriptional regulator hypoxia-inducible factor 1 (HIF-1). Within this narrow focus, general aspects of HIF-1 structure, function, and regulation will be described, data supporting the relevance of HIF-1 to human embryology and (patho)physiology will be summarized, and the therapeutic implications of these findings will be discussed.

	HIF-1 IS A bHLH-PAS PROTEIN

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

HIF-1 is a heterodimer consisting of HIF-1 and HIF-1 [also known as the aryl hydrocarbon nuclear translocator (ARNT)] subunits (68, 70). The amino-terminal half of each subunit contains basic helix-loop-helix (bHLH) and PER-ARNT-SIM homology (PAS) domains (Fig. 1). The bHLH domain defines a large superfamily of dimeric eukaryotic transcription factors in which the HLH domain mediates dimerization and the basic domain contacts DNA (reviewed in Ref. 57). The bHLH-PAS proteins represent a relatively small family of bHLH proteins that are only found in multicellular metazoan species (reviewed in Ref. 8). These proteins utilize both the HLH and PAS domains for dimerization. This family consists of two classes of proteins (class I and class II) that heterodimerize (Table 1).

View larger version (17K): [in this window] [in a new window]   Fig. 1.   Structure of hypoxia-inducible factor 1 (HIF-1). HIF-1 is an 826-amino-acid polypeptide, whereas HIF-1 is expressed as a 774- or 789-amino-acid polypeptide as a result of alternative splicing of an exon encoding 15 amino acids (a) immediately preceding the basic helix-loop-helix (bHLH) domain. bHLH and PER-aryl hydrocarbon nuclear translocator (ARNT)-SIM (PAS) domains are required for heterodimerization, which is, in turn, required for DNA binding. Additional regulatory domains of HIF-1 include amino- and carboxy-terminal nuclear localization signals (NLS-N and NLS-C, respectively), the proline-serine-threonine-rich protein stabilization domain (PSTD), amino- and carboxy-terminal transactivation domains (TAD-N and TAD-C, respectively), and the transcriptional inhibitory domain (ID). Transcriptional coactivators CBP and p300 interact with TAD-C. See text for details and references.

View this table: [in this window] [in a new window]   Table 1.   Mammalian bHLH-PAS proteins

Among the bHLH-PAS protein family, a subfamily of hypoxia-inducible transcription factor subunits has been discovered. The prototype, HIF-1, was isolated through an assay of its functional activity (68, 70), whereas the other members were identified by database searches for cDNA sequences encoding structurally related proteins. The amino acid sequences of important functional domains in HIF-1 (bHLH, PAS, proline-serine-threonine-rich protein stabilization domain, amino-terminal transactivation domain, and carboxy-terminal transactivation domain; see Fig. 1) are highly conserved in HIF-2 (49, 67, 73). As for all the class I subunits, HIF-1, -2, and -3 each heterodimerize with one of the class II subunits, ARNT (HIF-1), ARNT2, or ARNT3. It is not known whether heterodimers containing HIF-1 have different DNA-binding or transcriptional properties depending on the particular class I dimerization partner.

HIF-1 and ARNT (HIF-1) mRNA are expressed in most, if not all, human and rodent tissues (71, 72). In contrast, HIF-2, HIF-3, ARNT2, and ARNT3 show a more restricted pattern of expression. For example, mRNA encoding HIF-2 [also known as endothelial PAS domain protein 1 (EPAS1), HIF-1-like factor, HIF-1-related factor, and member of PAS domain family 2] is expressed in developing vascular endothelium, fetal lung, and catecholamine-producing cells (11, 15, 23, 30, 66, 67). It appears that HIF-1 plays a very general role by signaling the existence of hypoxia to the transcriptional machinery in the nucleus of all cells, whereas HIF-2 and HIF-3 play more limited or specialized roles in O₂ homeostasis, a hypothesis that is supported by comparative analyses of HIF-1 and HIF-2 knockout mice as described below.

The aryl hydrocarbon receptor (AHR)/ARNT heterodimer was the first mammalian bHLH-PAS protein to be characterized (5, 22). On binding of aryl hydrocarbons, AHR translocates to the nucleus, dimerizes with ARNT, and activates transcription of genes encoding cytochrome P-450s involved in metabolism of these compounds. PAS domains are found in proteins expressed in organisms of all three kingdoms (Archaea, Bacteria, and Eucarya) and in many cases serve to bind cofactors (e.g., chromophore, heme, or FAD) that allow the sensing of light, O₂ concentration, energy charge, or redox potential (reviewed in Ref. 64). Together, these findings suggest the possibility that HIF-1 (as well as HIF-2, HIF-3, and other class II bHLH-PAS proteins) may bind a cofactor through which the biological activity of the transcription factor could be modulated.

	REGULATION OF HIF-1 ACTIVITY

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

The biological activity of HIF-1 is determined by the expression and activity of the HIF-1 subunit (32-34, 58). The regulation of HIF-1 expression and activity in vivo occurs at multiple levels, including mRNA expression (2, 72, 75), protein expression (25, 26, 33, 36, 52, 55, 68, 75), nuclear localization (35), and transactivation (10, 34, 35, 52). Among these, the most intensively studied has been the regulation of steady-state HIF-1 protein levels. Under nonhypoxic conditions, HIF-1 appears to be ubiquitinated and subject to proteasomal degradation (25, 26, 36, 55). Iron chelators that, like hypoxia, also induce HIF-1 expression (69) prevent ubiquitination of HIF-1 (36). Decreased ubiquitination of HIF-1 in hypoxic cells has also been demonstrated (C. H. Sutter, E. Laughner, and G. L. Semenza, unpublished observations).

Renal carcinoma cell lines, which lack expression of the von Hipple-Lindau (VHL) tumor suppressor protein, maximally express HIF-1 and HIF-2 under nonhypoxic conditions and O₂-regulated expression is restored in cells that have been transfected with a VHL expression vector (47). VHL functions as a component of a ubiquitin-protein ligase (28, 40, 60), suggesting that the constitutive expression of HIF-1 is due to a lack of ubiquitination under nonhypoxic conditions, but this has not been demonstrated. Iron chelators disrupt the association of VHL and HIF-1, whereas these proteins remain associated in hypoxic cells (47). These data suggest a mechanism for the lack of ubiquitinated HIF-1 in cells treated with iron chelators (36) but do not provide the basis for regulation of HIF-1 protein stability by O₂ concentration. In addition, there are no data addressing whether VHL is involved in the regulation of HIF-1 in cell types other than renal carcinoma lines.

	HIF-1 TARGET GENES

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

To activate transcription of target genes, HIF-1 dimerizes with HIF-1 and the heterodimer binds to DNA at sites represented by the consensus sequence 5'-RCGTG-3' (58). The HIF-1 binding site is present within a hypoxia response element, a cis-acting transcriptional regulatory sequence that can be located within 5'-flanking, 3'-flanking, or intervening sequences of target genes. The presence of an intact HIF-1 binding site is necessary, but not sufficient, for these elements to mediate transcriptional activation (58, 59). The number of target genes activated by HIF-1 continues to increase and includes genes whose protein products are involved in angiogenesis, energy metabolism, erythropoiesis, cell proliferation and viability, vascular remodeling, and vasomotor responses (Table 2).

View this table: [in this window] [in a new window]   Table 2.   HIF-1 target genes

	HIF-1 IS REQUIRED FOR EMBRYOGENESIS

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

Mice homozygous for a loss-of-function mutation in the gene encoding HIF-1 (29, 54) or HIF-1 (43) die at midgestation with vascular defects primarily involving the embryonic and extraembryonic circulation, respectively. In the case of Hif1a^/ mice, which lack HIF-1, vasculogenesis initiates normally but by embryonic day 9 a marked regression of vascular endothelium in the cephalic region occurs (29). The vascular defect is preceded by the death of premigratory and postmigratory cephalic neural crest cells (29, 38). These mesenchymal cells are progenitors of pericytes that are required for maintenance of blood vessel integrity at this stage of development, suggesting that mesenchymal cell death contributes to the vascular defect in Hif1a^/ mice. Hif1a^/ mice also have defects in cardiac morphogenesis and neural tube closure (29, 38). In contrast to the global and early effects of HIF-1 deficiency, Epas1^/ mice, which lack expression of HIF-2, die later in development due to a specific defect in catecholamine production (66). Despite the prominent expression of HIF-2 in the vascular endothelium of wild-type mice, Epas1^/ mice have no obvious vascular defects, suggesting that HIF-1 expression in these cells (75) may be sufficient for normal development. However, the role of HIF-2 in vascular development within specific organs, such as the lung (11), warrants further study.

	INVOLVEMENT OF HIF-1 IN THE PATHOPHYSIOLOGY OF HYPOXIC PULMONARY HYPERTENSION

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

In contrast to Hif1a^/ mice, Hif1a^+/ mice develop normally and are indistinguishable from wild-type littermates. However, when exposed to 10% O₂ for 1-6 wk, classic (patho)physiological responses to hypoxia, such as increases in hematocrit, right ventricular mass, and right ventricular pressure, are impaired in Hif1a^+/ mice relative to their wild-type littermates (76). To investigate the effects of HIF-1 deficiency on remodeling of pulmonary arterioles, histological sections of lungs from Hif1a^+/ and Hif1a^+/+ mice exposed to 10% O₂ for 3 wk were prepared for morphometric analysis. The proportion of nonmuscularized, partially muscularized, and completely muscularized pulmonary arterioles with an external diameter of 100 µm in Hif1a^+/ and Hif1a^+/+ mice was significantly different by ² analysis (P = 0.00001), with fewer completely muscularized and more nonmuscularized arterioles in the lungs of the Hif1a^+/ mice (76). The wall thickness of completely muscularized pulmonary arterioles with a diameter of 100 µm was also significantly reduced in Hif1a^+/ mice (P < 0.001). These results indicate that not only did chronically hypoxic Hif1a^+/ mice have fewer completely muscularized pulmonary arterioles but the degree of muscularization in such vessels was reduced. Thus HIF-1 plays a major role in mediating pulmonary vascular remodeling in response to chronic hypoxia. Several known HIF-1 target genes [e.g., erythropoietin (EPO), endothelin-1 (ET-1), insulin-like growth factor 2 (IGF-2), nitric oxide synthase 2 (NOS2), and vascular endothelial growth factor (VEGF); see Table 2] may be involved in these responses, and others will likely be identified in future studies. Local inhibition of HIF-1 activity in the lung by inhalation therapy may provide a means of preventing or retarding the development of this lethal complication of chronic lung disease in at-risk individuals. A dominant-negative form of HIF-1 that might be suitable for gene therapy applications has been described (16, 32). However, a specific small-molecule inhibitor of HIF-1 activity would also have great potential therapeutic utility.

	INVOLVEMENT OF HIF-1 IN ISCHEMIC NEOVASCULARIZATION

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

The role of HIF-1 in the activation of VEGF gene transcription in hypoxic cells is well established (6, 16, 29, 54) as is the role of VEGF in mediating ischemic neovascularization (reviewed in Ref. 14). In near-term fetal sheep subjected to isovolemic hemorrhage in utero, the development of cardiac hypertrophy was associated with increased expression of HIF-1 protein as well as VEGF mRNA and protein and increased myocardial vascularization (44). A similar correlation between HIF-1 protein and VEGF mRNA expression was established in a mouse model of ischemic retinopathy (50). Clinical trials are currently evaluating the safety and efficacy of administration of VEGF protein or DNA as a means of promoting increased vascularization within ischemic tissue. However, the expression of multiple VEGF isoforms and other angiogenic factors such as the angiopoietins may be required for optimal vascular development. HIF-1 gene therapy has the theoretical benefit of inducing the expression of multiple factors that promote angiogenesis and/or myocardial cell survival. Preclinical studies are currently underway to examine the therapeutic potential of this approach.

	INVOLVEMENT OF HIF-1 IN PROMOTING OR PREVENTING ISCHEMIC CELL DEATH

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

Several recent studies have provided evidence in support of the hypothesis that HIF-1 mediates the death of cultured cells subjected to O₂ and/or glucose deprivation (6, 19), possibly by associating with, and preventing the degradation of, p53 (1). One study, which utilized mouse embryonic stem cells, implied that HIF-1 has a proapoptotic role in tumor cells (6), a conclusion that appears unfounded especially in advanced cancers with p53 loss of function (see below). Another study, which utilized cultured cortical neurons, implied that HIF-1 promotes cell death in the context of cerebral ischemia (19). However, after middle cerebral artery occlusion in rats, increased expression of mRNA encoding HIF-1 and glycolytic enzymes was induced in the penumbra, which is the viable cortical tissue surrounding the infarct (2). Further studies are required to determine whether this response contributed to the survival of these cells. The presently available data are not sufficient to draw any final conclusions, and studies of Hif1a^+/ mice may provide a means to determine the net effect of HIF-1 expression on cell viability during acute cerebral or myocardial ischemia.

Finally, second-window (delayed) models of cerebral and myocardial ischemic preconditioning have been described that involve de novo gene expression, suggesting a possible role for HIF-1 in this process. The implication of NOS2 gene expression in myocardial preconditioning (63) and the ability of HIF-1 to activate transcription of this gene (48, 51) are particularly provocative. Nuclear factor (NF)-B has also been implicated in preconditioning and NOS2 gene expression (45), suggesting the possibility that HIF-1 and NF-B may act synergistically to activate NOS2 transcription.

	INVOLVEMENT OF HIF-1 IN CANCER

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

Tumor progression to the lethal phenotype in which cells become capable of invasion and metastasis is associated with adaptation to hypoxia, and there is an inverse correlation between tumor oxygenation and clinical outcome (4, 21). Tumor cells lacking HIF-1 expression are markedly impaired in their growth and vascularization when injected into nude mice (31, 46). Among prostate cancer cell lines, the level of HIF-1 expression is correlated with the biological behavior of the cells in xenograft assays (78). Mutations that activate oncogenes (e.g., v-src) or inactivate tumor suppressor genes (e.g., VHL) are associated with increased expression of HIF-1 protein and HIF-1 DNA binding and transcriptional activity and the expression of downstream genes encoding glycolytic enzymes and VEGF (31, 46, 47). Increased HIF-1 expression in tumors can also result from activation of autocrine growth factor stimulation. IGF-2 induces expression of HIF-1, which is in turn required for IGF-2 gene expression (13). IGF-2 is the most highly upregulated gene in colon cancer (77), thus providing a mechanism for the increased HIF-1 expression, which has been observed in this neoplasm (79). Thus HIF-1 is overexpressed in tumors as a result of physiological signals (hypoxia) and genetic alterations. These data suggest that inhibition of HIF-1 activity may represent a novel therapeutic approach to cancer therapy, especially in combination with angiogenesis inhibitors, which would further increase intratumoral hypoxia and thus provide an even greater therapeutic window for use of an HIF-1 inhibitor.

	CONCLUSION

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

HIF-1 plays major roles in development, physiology, and pathophysiology. Modulation of HIF-1 activity may be of therapeutic utility in patients with cancer, chronic lung disease, and/or ischemic cardiovascular disease.

	ACKNOWLEDGEMENTS

Work in the author's laboratory is supported by grants from the American Heart Association Maryland Affiliate, Children's Brain Tumor Foundation, National Institutes of Health (R01-DK-39869, R01-HL-55338), and Genzyme Corporation, which has also been granted a license by the Johns Hopkins University for HIF-1 gene therapy of cardiovascular disorders. The terms of this arrangement are being managed by the University in accordance with its conflict of interest policies.

	FOOTNOTES

First in a series of invited mini-reviews on "Hypoxia Influence on Gene Expression."

Address for reprint requests and other correspondence: G. L. Semenza, Johns Hopkins Hospital, CMSC-1004, 600 North Wolfe St., Baltimore, MD 21287-3914 (E-mail: gsemenza{at}jhmi.edu).

	REFERENCES

TOP ABSTRACT PHYSIOLOGICAL RESPONSES TO... HIF-1 IS A bHLH-PAS... REGULATION OF HIF-1 ACTIVITY HIF-1 TARGET GENES HIF-1 IS REQUIRED FOR... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... INVOLVEMENT OF HIF-1 IN... CONCLUSION REFERENCES

1.   An, WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, and Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1. Nature 392: 405-408, 1998[Medline].

2.   Bergeron, M, Yu AY, Solway KE, Semenza GL, and Sharp FR. Induction of hypoxia-inducible factor 1 (HIF-1) and its target genes following focal ischemia in rat brain. Eur J Neurosci 11: 4159-4170, 1999[ISI][Medline].

3.   Bhattacharya, S, Michels CL, Leung M-K, Arany ZP, Kung AL, and Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13: 64-75, 1999[Abstract/Free Full Text].

4.   Brizel, DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, and Dewhirst MW. Tumor oxygenation predicts the likelihood of distant metastases in human soft tissue sarcomas. Cancer Res 56: 941-943, 1996[Abstract/Free Full Text].

5.   Burbach, KM, Poland A, and Bradfield CA. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA 89: 8185-8189, 1992[Abstract/Free Full Text].

6.   Carmeliet, P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, and Keshet E. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis. Nature 394: 485-490, 1998[Medline].

7.   Cormier-Regard, S, Nguyen SV, and Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 273: 17787-17792, 1998[Abstract/Free Full Text].

8.   Crews, ST, and Fan C-M. Remembrance of things PAS: regulation of development by bHLH-PAS proteins. Curr Opin Genet Dev 9: 580-587, 1999[ISI][Medline].

9.   Eckhart, AD, Yang N, Xin X, and Faber JE. Characterization of the _1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc Natl Acad Sci USA 94: 9487-9492, 1997[Abstract/Free Full Text].

10.   Ema, M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1 in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914, 1999[ISI][Medline].

11.   Ema, M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 regulates VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278, 1997[Abstract/Free Full Text].

12.   Fan, C-M, Kuwana E, Bulfone A, Fletcher CF, Copeland NG, Jenkins NA, Crews S, Martinez S, Puelles L, Rubenstein J, and Tessier-Lavigne M. Expression patterns of two murine homologues of Drosophila single-minded suggest possible roles in embryonic patterning and in the pathogenesis of Down syndrome. Mol Cell Neurosci 7: 1-16, 1996[ISI][Medline].

13.   Feldser, D, Agani F, Iyer NV, Pak B, Ferreira G, and Semenza GL. Reciprocal postive regulation of hypoxia-inducible factor 1 and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999[Abstract/Free Full Text].

14.   Ferrara, N, and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997[Abstract/Free Full Text].

15.   Flamme, I, Frohlich T, von Reutern M, Kappel A, Damert A, and Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor 1 and developmentally expressed in blood vessels. Mech Dev 63: 51-60, 1997[ISI][Medline].

16.   Forsythe, JA, Jiang B-H, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996[Abstract].

17.   Gerber, H-P, Condorelli F, Park J, and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 272: 23659-23667, 1997[Abstract/Free Full Text].

18.   Gu, Y-Z, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA. Molecular characterization and chromosomal localization of a third -class hypoxia inducible factor subunit, HIF3. Gene Expr 7: 205-213, 1998[ISI][Medline].

19.   Halterman, MW, Miller CC, and Federoff HJ. Hypoxia-inducible factor 1 mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci 19: 6618-6624, 1999.

20.   Hirose, K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, Saijo Y, Gotoh O, Sogawa K, and Fujii-Kuriyama Y. cDNA cloning and tissue-specific expression of a novel basic-helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 16: 1706-1713, 1996[Abstract].

21.   Hockel, M, Schlenger K, Aral B, Jitze M, Schaffer U, and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996[Abstract/Free Full Text].

22.   Hoffman, EC, Reyes H, Chu F-F, Snader F, Conley LH, Brooks BA, and Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252: 954-958, 1991[Abstract/Free Full Text].

23.   Hogenesch, JB, Chan WK, Jackiw VH, Brown RC, Gu Y-Z, Pray-Grant M, Perdew GH, and Bradfield CA. Characterization of a subset of the basic helix-loop-helix-PAS superfamily that interacts with components of the dioxin signalling pathway. J Biol Chem 272: 8581-8593, 1997[Abstract/Free Full Text].

24.   Hu, J, Discher DJ, Bishopric NH, and Webster KA. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 245: 894-899, 1998[ISI][Medline].

25.   Huang, LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its  subunit. J Biol Chem 271: 32253-32259, 1996[Abstract/Free Full Text].

26.   Huang, LE, Gu J, Schau M, and Bunn HF. Regulation of hypoxia-inducible factor 1 is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998[Abstract/Free Full Text].

27.   Ikeda, M, and Nomura M. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage. Biochem Biophys Res Commun 233: 258-264, 1997[ISI][Medline].

28.   Iwai, K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, and Pause A. Identification of the von Hippel-Lindau tumor-supressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441, 1999[Abstract/Free Full Text].

29.   Iyer, NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, and Semenza GL. Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1. Genes Dev 12: 149-162, 1998[Abstract/Free Full Text].

30.   Jain, S, Maltepe E, Lu MM, Simon C, and Bradfield CA. Expression of ARNT, ARNT2, HIF1, HIF2 and Ah receptor mRNAs in the developing mouse. Mech Dev 73: 117-123, 1998[ISI][Medline].

31.   Jiang, B-H, Agani F, Passaniti A, and Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997[Abstract/Free Full Text].

32.   Jiang, B-H, Rue E, Wang GL, Roe R, and Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778, 1996[Abstract/Free Full Text].

33.   Jiang, B-H, Semenza GL, Bauer C, and Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O₂ tension. Am J Physiol Cell Physiol 271: C1172-C1180, 1996[Abstract/Free Full Text].

34.   Jiang, B-H, Zheng JZ, Leung SW, Roe R, and Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1: modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 19253-19260, 1997[Abstract/Free Full Text].

35.   Kallio, PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, and Poellinger L. Signal transduction in hypoxic cells: inducible nuclear localization and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1. EMBO J 17: 6573-6586, 1998[ISI][Medline].

36.   Kallio, PJ, Wilson WJ, O'Brien S, Makino Y, and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1 by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525, 1999[Abstract/Free Full Text].

37.   King, DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M., Antoch MP, Steeves TD, Vitaterna MH, Kornhauser JM, Lowrey PL, Turek FW, and Takahashi JS. Positional cloning of the mouse circadian clock gene. Cell 89: 641-653, 1997[ISI][Medline].

38.   Kotch, LE, Iyer NV, Laughner E, and Semenza GL. Defective vascularization of HIF-1-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209: 254-267, 1999[ISI][Medline].

39.   Lee, PJ, Jiang B-H, Chin BY, Iyer NV, Alam J, Semenza GL, and Choi AMK Hypoxia-inducible factor 1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375-5381, 1997[Abstract/Free Full Text].

40.   Lisztwan, J, Imbert G, Wirbelauer C, Gstaiger M, and Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13: 1822-1833, 1999[Abstract/Free Full Text].

41.   Lok, CN, and Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274: 24147-24152, 1999[Abstract/Free Full Text].

42.   Lopez-Barneo, J, and Weir EK. Oxygen Regulation of Ion Channels and Gene Expression. New York: Futura, 1998.

43.   Maltepe, E, Schmidt JV, Baunoch D, Bradfield CA, and Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403-407, 1997[Medline].

44.   Martin, C, Yu AY, Jiang B-H, Davis L, Kimberly D, Hohimer AR, and Semenza GL. Cardiac hypertrophy in chronically anemic fetal sheep: increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 178: 527-534, 1998[ISI][Medline].

45.   Maulik, N, Sato M, Price BD, and Das DK. An essential role of NFB in tyrosine kinase signalling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 429: 365-369, 1998[ISI][Medline].

46.   Maxwell, PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997[Abstract/Free Full Text].

47.   Maxwell, PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999[Medline].

48.   Melillo, G, Musso T, Sica A, Taylor LS, Cox GW, and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182: 1683-1693, 1995[Abstract/Free Full Text].

49.   O'Rourke, JF, Tian Y-M, Ratcliffe PJ, and Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1. J Biol Chem 274: 2060-2071, 1999[Abstract/Free Full Text].

50.   Ozaki, H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, and Campochiaro PA. Hypoxia inducible factor 1 is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40: 182-189, 1999[Abstract/Free Full Text].

51.   Palmer, LA, Semenza GL, Stoler MH, and Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol Lung Cell Mol Physiol 274: L212-L219, 1998[Abstract/Free Full Text].

52.   Pugh, CW, O'Rourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the  subunit. J Biol Chem 272: 11205-11214, 1997[Abstract/Free Full Text].

53.   Rolfs, A, Kvietikova I, Gassmann M, and Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272: 20055-20562, 1997[Abstract/Free Full Text].

54.   Ryan, HE, Lo J, and Johnson RS. HIF-1 is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998[ISI][Medline].

55.   Salceda, S, and Caro J. Hypoxia-inducible factor 1 (HIF-1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends upon redox-induced changes. J Biol Chem 272: 22642-22647, 1997[Abstract/Free Full Text].

56.   Semenza, GL. Perspectives on oxygen sensing. Cell 98: 281-284, 1999[ISI][Medline].

57.   Semenza, GL. Transcription Factors and Human Disease. New York: Oxford University Press, 1998.

58.   Semenza, GL, Jiang B-H, Leung SW, Passantino R, Concordet J-P, Maire P, and Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996[Abstract/Free Full Text].

59.   Semenza, GL, and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992[Abstract/Free Full Text].

60.   Stebbins, CE, Kaelin WG, Jr, and Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-460, 1999[Abstract/Free Full Text].

61.   Tacchini, L, Bianchi L, Bernelli-Zazzera A, and Cairo G. Transferrin receptor induction by hypoxia: HIF-1-mediated transcriptional activation and cell-specific posttranscriptional regulation. J Biol Chem 274: 24142-24146, 1999[Abstract/Free Full Text].

62.   Takahata, S, Sogawa K, Kobayashi A, Ema M, Mimura J, Ozaki N, and Fujii-Kuriyama Y. Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and Clock. Biochem Biophys Res Commun 248: 789-794, 1998[ISI][Medline].

63.   Takano, H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon AK, Zhang Q, and Bolli R. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 98: 441-449, 1998[ISI][Medline].

64.   Taylor, BL, and Zhulin IB. PAS domains: internal sensors of oyxgen, redox potential, and light. Microbiol Mol Biol Rev 63: 479-506, 1999[Abstract/Free Full Text].

65.   Tazuke, SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen L-F, Irwin JC, Powell DR, Giaccia AJ, and Giudice LC. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA 95: 10188-10193, 1998[Abstract/Free Full Text].

66.   Tian, H, Hammer RE, Matsumoto AM, Russell DW, and McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998[Abstract/Free Full Text].

67.   Tian, H, McKnight SL, and Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997[Abstract/Free Full Text].

68.   Wang, GL, Jiang B-H, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995[Abstract/Free Full Text].

69.   Wang, GL, and Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615, 1993[Abstract/Free Full Text].

70.   Wang, GL, and Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237, 1995[Abstract/Free Full Text].

71.   Wenger, RH, Rolfs A, Marti HH, Guenet J-L, and Gassmann M. Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor 1. Biochem Biophys Res Commun 223: 54-59, 1996[ISI][Medline].

72.   Wiener, CM, Booth G, and Semenza GL. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225: 485-488, 1996[ISI][Medline].

73.   Wiesener, MS, Turley H, Allen WE, William C, Eckardt K-U, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, and Maxwell PH. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1. Blood 92: 2260-2268, 1998[Abstract/Free Full Text].

74.   Wood, SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, and Ratcliffe PJ. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1-subunit (HIF-1): characterization of HIF-1-dependent and independent hypoxia-inducible gene expression. J Biol Chem 273: 8360-8368, 1998[Abstract/Free Full Text].

75.   Yu, AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, and Semenza GL. Temporal, spatial and oxygen-regulated expression of hypoxia-inducible factor 1 in the lung. Am J Physiol Lung Cell Mol Physiol 275: L818-L826, 1998[Abstract/Free Full Text].

76.   Yu, AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JSK, Wiener CM, Sylvester JT, and Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1. J Clin Invest 103: 691-696, 1999[ISI][Medline].

77.   Zhang, L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, and Kinzler K. Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997[Abstract/Free Full Text].

78.   Zhong, H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, and Semenza GL. Increased expression of hypoxia inducible factor-1 in rat and human prostate cancer. Cancer Res 58: 5280-5284, 1998[Abstract/Free Full Text].

79.   Zhong, H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW. Overexpression of hypoxia-inducible factor 1 in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999[Abstract/Free Full Text].

80.   Zhou, Y-D, Barnard M, Tian H, Li X, Ring HZ, Francke U, Shelton J, Richardson J, Russell DW, and McKnight SL. Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci USA 94: 713-718, 1997[Abstract/Free Full Text].